Spinout from Nobel-winning Berkeley lab cuts cancer cell therapy deal with drug giant AbbVie
Caribou Biosciences Inc. — one of the first companies to spin Nobel Prize-winning UC Berkeley professor Jennifer Doudna's CRISPR genome-editing technology out of her lab — inked a deal with drug giant AbbVie Inc. to help develop an off-the-shel.....»»
Buffalo-based biotech startup inks deal with Chinese pharma giant worth up to $148 million
MimiVax has long presented an exciting opportunity to develop a cutting-edge cancer therapy in Buffalo. Now the spinout from Roswell Park Comprehensive Cancer Center is a lot closer to that goal. The company – which is developing an anti-cancer .....»»
In major cell therapy manufacturing deal, UCSF, biotech tools leader Thermo Fisher go small to go big
The new cell therapy manufacturing facility, which will open early next year, will be able to deliver highly specialized cell therapies to patients in clinical trials at UCSF's women's, children's and cancer hospitals complex across Mariposa Street......»»
The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 16) read more.....»»
In deal with Gilead, stealthy East Bay startup turns cell therapy against autoimmune diseases
Cell therapy's initial applications have been in cancer. This deal could rev up its use against a wide range of diseases where the immune system goes wild and attacks the body......»»
Novartis wins Medicaid approval for new sickle cell drug in key U.S. states
Novartis AG has secured Medicaid coverage for a pricey new sickle cell disease therapy in two U.S. states just weeks after winning U.S. approval, following an early campaign to convince local officials of its value, a.....»»
Blackstone to invest $400 million in gene therapy venture with Ferring
Blackstone Group Inc said on Monday it will invest $400 million in a joint venture with Swiss drug company Ferring that is working on an experimental gene therapy for bladder cancer, the private equity giant's largest ever bet on drug development......»»
Shares of cancer-therapy companies skyrocket after Pfizer acquisition news
Shares of gene-therapy companies shot up on Monday after Pfizer Inc. announced it would acquire cancer drug maker Array BioPharma Inc. in a deal worth up to $11.4 billion......»»
How this biotech nearly tripled its IPO price with a buyout in less than 4 months
Pharma giant Eli Lilly and Co. will buy small cancer immunotherapy drug developer ARMO BioSciences Inc., a Redwood City company that went public in January, in a $1.6 billion all-cash deal. Lilly's $50-per-share buyout is nearly three times ARMO's (.....»»
Here"s how Redwood City biotech tripled its IPO price with a buyout in less than 4 months
Pharma giant Eli Lilly and Co. will buy small cancer immunotherapy drug developer ARMO BioSciences Inc., a Redwood City company that went public in January, in a $1.6 billion all-cash deal. Lilly's $50-per-share buyout is nearly three times ARMO's (NA.....»»
GlaxoSmithKline and Merck KGaA strike immunotherapy deal worth up to $4 billion
U.K.-based GlaxoSmithKline Plc  and Germany-based Merck KGaA are entering a partnership to develop and commercialize a therapy for patients with advanced non-small cell lung cancer in a deal worth up to $4.23 billion, the companies announced Tuesday......»»
Johnson & Johnson to buy robotic surgery company for $3.4B
Johnson & Johnson has agreed to buy surgical robotics company Auris Health Inc. for about $3.4 billion in cash, in a deal that would give the drug giant a lung-cancer diagnostic and treatment tool......»»
Johnson & Johnson to buy robotic surgery company for $3.4B
Johnson & Johnson has agreed to buy surgical robotics company Auris Health Inc. for about $3.4 billion in cash, in a deal that would give the drug giant a lung-cancer diagnostic and treatment tool......»»
Drug giant Merck acquires Seattle biotech Immune Design for $300 million
The deal comes four months after Immune Design Corp. halted its lead cancer vaccine trial and restructured its drug development plans......»»
Small-Cap Cancer Drug Developer Agenus" Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom
The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity. Latest Ratings for A.....»»
Vertex to study experimental gene-editing therapy as treatment for sickle cell, beta-thalassemia
Vertex Pharmaceuticals Inc. said Tuesday it plans to pay $1.1 billion to Crispr Therapeutics AG as part of a deal to test an experimental gene-editing therapy for sickle cell disease and transfusion-dependent beta-tha.....»»
Gilead"s virology drug head named CEO of East Coast biotech AlloVir
Dr. Diana Brainard, a 10-year veteran of Gilead Sciences Inc. who currently heads up the company's broad virology drug pipeline, will take over as CEO of a young cell therapy company backed by her soon-to-be former employer. Starting May 17, Brain.....»»
Immatics Stock Trading Higher As Cell Therapy Program Shows Anti-Tumor Activities In Pretreated Cancer Patients
Immatics NV (NASDAQ: IMTX) has announced a clinical data update from the dose-escalation cohorts of the ongoing Phase 1 trial evaluating its ACTengine product candidates IMA201, IMA202, and IMA read more.....»»
Inovio spinout Geneos closes $12M financing round to advance personalized cancer therapy
The Montgomery County biopharmaceutical company's initial target is a type of liver cancer known as advanced hepatocellular carcinoma......»»
Bluebird Bio Temporarily Suspends Sickle Cell Gene Therapy Studies Following Incidences of Blood Cancer
Shares of bluebird bio Inc (NASDAQ: BLUE) were sinking Tuesday morning following an adverse clinical pipeline development. read more.....»»